Published in Eur J Cancer on March 01, 2004
Capecitabine in Metastatic Breast and GI Cancers (X7-7) | NCT02595320
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncol (2015) 5.54
Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2010) 1.59
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat (2009) 1.19
Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. Cancer Chemother Pharmacol (2008) 1.01
Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist (2011) 0.98
Acceptance of oral chemotherapy in breast cancer patients - a survey study. BMC Cancer (2011) 0.96
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol (2010) 0.95
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol (2010) 0.93
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. Br J Cancer (2004) 0.88
Management of advanced breast cancer with the epothilone B analog, ixabepilone. Drug Des Devel Ther (2009) 0.85
Response of cutaneous metastases from breast cancer to capecitabine. Clin Med Oncol (2008) 0.85
Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine. Springerplus (2015) 0.85
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer (2006) 0.84
Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more. Mol Clin Oncol (2012) 0.83
Favorable clinical course of patients experiencing bevacizumab-induced proteinuria. Case Rep Oncol (2010) 0.82
Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy. Curr Oncol (2012) 0.81
A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes. Cancer Biol Ther (2015) 0.81
Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer. Braz J Med Biol Res (2013) 0.81
A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. J Cancer Res Clin Oncol (2010) 0.80
A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol (2013) 0.80
Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430. Oncologist (2012) 0.79
Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study. Br J Cancer (2014) 0.79
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer. Breast Cancer (Auckl) (2016) 0.79
Chemotherapy with low-dose capecitabine as palliative treatment in a patient with metastatic breast cancer: a case report. Cases J (2009) 0.79
Efficacy of Vitamin E Treatment for Hand-Foot Syndrome in Patients Receiving Capecitabine. Breast Care (Basel) (2010) 0.79
Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer. Invest New Drugs (2012) 0.78
A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat (2016) 0.76
A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. Support Care Cancer (2014) 0.75
A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials. Onco Targets Ther (2016) 0.75
Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. Onco Targets Ther (2016) 0.75
Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine. Cancer Med (2015) 0.75
Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. Cancers (Basel) (2016) 0.75
The comparison of maintenance treatment with capecitabine (CMT) and non-maintenance treatment with capecitabine (non-CMT) in patients with metastatic breast cancer. Int J Clin Exp Med (2015) 0.75
Gemcitabine single or combination chemotherapy in post anthracycline and taxane salvage treatment of metastatic breast cancer: retrospective analysis of 124 patients. Cancer Res Treat (2006) 0.75
Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study. Medicine (Baltimore) (2015) 0.75
Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study. Clin Med Oncol (2008) 0.75
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer. Clin Breast Cancer (2017) 0.75
5-Fluorouracil versus 5-fluorouracil plus alpha-interferon as treatment of metastatic colorectal carcinoma. A randomized study. Ann Oncol (1996) 3.10
Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol (2008) 3.07
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol (2002) 2.61
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol (1996) 2.17
Primordial role of CD34+ 38- cells in early and late trilineage haemopoietic engraftment after autologous blood cell transplantation. Br J Haematol (1998) 2.10
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer (1997) 2.04
Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice. Br J Cancer (1999) 1.96
Cancer genetics clinics: target population and consultees' expectations. Eur J Cancer (1996) 1.88
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol (2012) 1.82
Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial) Ann Oncol (2000) 1.80
The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer (2000) 1.74
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol (1997) 1.67
Ductal carcinoma in situ of the male breast. Analysis of 31 cases. Eur J Cancer (1997) 1.67
Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol (1993) 1.60
Value of CA 15:3 in the follow-up of breast cancer patients. Br J Cancer (1987) 1.58
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol (2005) 1.54
P53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-up. Ann Oncol (2000) 1.53
Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood (2001) 1.51
Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial. Gynecol Oncol (2009) 1.50
Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol (2006) 1.44
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol (2013) 1.41
Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat (2002) 1.39
High failure rate of carboplatin-etoposide combination in good risk non-seminomatous germ cell tumours. Eur J Cancer (1993) 1.39
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol (1995) 1.32
HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol (2004) 1.31
Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res (2000) 1.30
Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol (2009) 1.25
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res (2003) 1.24
Five-year change in statistical designs of phase II trials published in leading cancer journals. Eur J Cancer (2004) 1.24
Desmoplastic small round cell tumors: results of a four-drug chemotherapy regimen in five adult patients. Cancer (1996) 1.23
Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer (1997) 1.23
Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol (2008) 1.23
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer (2002) 1.22
Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet (1986) 1.22
The human homologue of the putative proto-oncogene Spi-1: characterization and expression in tumors. Oncogene (1990) 1.21
Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J (2001) 1.20
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol (2001) 1.20
Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer (2003) 1.20
Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol (2009) 1.18
Prognostic value of continuous variables in breast cancer and head and neck cancer. Dependence on the cut-off level. Br J Cancer (1988) 1.17
Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer (1992) 1.17
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol (1996) 1.13
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol (1998) 1.12
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer (2012) 1.11
Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol (2007) 1.11
Attitudes towards cancer predictive testing and transmission of information to the family. J Med Genet (1996) 1.08
Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int (2003) 1.07
Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology (2001) 1.07
Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse. Eur J Cancer (2001) 1.06
Reversible posterior leukoencephalopathy syndrome after carboplatin therapy. Ann Oncol (2006) 1.05
Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer (2003) 1.05
Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy. J Clin Oncol (1998) 1.04
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol (2003) 1.04
Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer (1992) 1.04
Adult granulosa-cell tumor of the ovary: a retrospective study of 45 cases. Int J Gynecol Cancer (1997) 1.03
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol (2005) 1.01
Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br J Cancer (2009) 1.00
Age-related difference in tamoxifen disposition. Clin Pharmacol Ther (1996) 0.99
The DNA labelling index: a prognostic factor in node-negative breast cancer. Breast Cancer Res Treat (1987) 0.99
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br J Cancer (1996) 0.99
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques. J Clin Oncol (2000) 0.99
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res (1994) 0.99
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Br J Cancer (2007) 0.98
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol (2005) 0.98
Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer (1991) 0.98
Local and distant failures after limited surgery with positive margins and radiotherapy for node-negative breast cancer. Int J Radiat Oncol Biol Phys (2000) 0.98
Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. Ann Oncol (2001) 0.98
Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? Br J Cancer (2003) 0.97
Survival data relating to the use of goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer (1993) 0.96
Male breast cancer and the androgen receptor gene. Nat Genet (1993) 0.96
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer (1999) 0.96
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer (2004) 0.95
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol (2002) 0.95
Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer (1999) 0.95
Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol (1993) 0.94
Neoadjuvant endocrine therapy in breast cancer. Breast (2005) 0.94
Androgen receptor gene mutation in male breast cancer. Hum Mol Genet (1993) 0.94
Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int J Cancer (1988) 0.94
Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer (1999) 0.94
Prompt resolution of acute disseminated intravascular coagulation with docetaxel and cisplatin in hormone refractory prostate cancer. J Urol (2002) 0.94